Zymfentra Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The zymfentra market research report is one of a series of new reports that provides zymfentra market statistics, including zymfentra industry global market size, regional shares, competitors with a zymfentra market share, detailed zymfentra market segments, market trends and opportunities, and any further data you may need to thrive in the zymfentra industry. This zymfentra market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast period can be attributed to a rise in clinical efficacy and evidence, a surge in innovative formulations and delivery methods, an increase in partnerships and collaborations, growth in patient advocacy and awareness, and an increase in physician awareness and adoption. Major trends in the forecast period include an increase in personalized medicine, technological advancements in drug delivery, an increasing focus on rare disease treatment, expansion in telemedicine, and growth in digital health.

The growth of the Zymfentra market is expected to be significantly influenced by the rising aging population. As life expectancy increases and birth rates decline, a larger proportion of the global population is reaching older age. This demographic shift presents an opportunity for treatments such as Zymfentra, which is crucial for managing chronic inflammatory diseases that tend to become more common with age. By offering a convenient and effective solution, Zymfentra helps reduce the need for frequent hospital visits, making it especially beneficial for elderly individuals. For instance, according to the World Health Organization, by 2030, one in six people worldwide will be over 60 years old, and the population in this age group will rise from 1 billion in 2020 to 1.4 billion. The number of people aged 80 and older is expected to triple by 2050, further driving the demand for treatments such as Zymfentra in the aging population.

The increase in healthcare investments is another factor expected to propel the Zymfentra market. Healthcare investments refer to the capital allocated across various sectors, such as pharmaceuticals, biotechnology, medical devices, and healthcare services, to foster medical innovations and improve patient care. The growing demand for advanced healthcare services, particularly due to the aging population and heightened health awareness, is driving these investments. By funding research, supporting regulatory approvals, and improving healthcare infrastructure, these investments make treatments such as Zymfentra more accessible to a broader patient population. For example, in May 2024, the UK’s healthcare expenditure reached approximately $366 billion, marking a significant increase in healthcare investments. Such financial allocations help ensure the development and availability of advanced treatments such as Zymfentra.

A key trend in the Zymfentra market is the approval of innovative drugs, which provides companies with a competitive advantage in the industry. Regulatory approval is the process through which authorities assess and authorize new drugs based on their safety, efficacy, and clinical trial results. For instance, in October 2023, Celltrion Inc. announced that the U.S. Food and Drug Administration had approved Zymfentra (infliximab-dyyb), a subcutaneous version of the drug that allows patients to administer it at home. This approval benefits patients with conditions such as Crohn's disease, rheumatoid arthritis, and psoriasis by offering a quicker, more convenient administration method, reducing the need for hospital visits, and improving patient adherence to treatment regimens.

The key company operating in the zymfentra market is Celltrion Inc.

North America was the largest region in the zymfentra market in 2024. The regions covered in zymfentra report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the zymfentra market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Zymfentra is a medication used for enzyme replacement therapy (ERT) in patients with certain rare genetic disorders, particularly those affecting the metabolism of complex sugars. It works by providing the missing or deficient enzyme, helping to alleviate symptoms and improve the quality of life for individuals with these conditions.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main indications for zymfentra include ulcerative colitis, Crohn's disease, and rheumatoid arthritis. Ulcerative colitis is a chronic inflammatory condition that affects the lining of the large intestine and rectum, leading to ulcers and irritation. Zymfentra is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and is used by adult and geriatric patients.

The zymfentra market consists of sales of biosimilars, immunomodulators, monoclonal antibodies and intravenous infusion medications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.